|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pharmacokinetics and pharmacodynamics of amoxicillin-sulbactam,a novel aminopenicillin-beta-lactamase inhibitor combination against Escherichia coli显示文摘 | Bantar C Nicola F Arenoso H | 1999 | Antimicrob Agents Chemother1999，43，6： | 1 |
| 2 | Three-year surveillance study of nosocomial bacterial resistance in Argentina显示文摘 | Bantar C Famiglietti A Goldberg M | 2000 | Int J Infect Dis2000，4，2： | 1 |
| 3 | Pharmacokinetics and pharmacodynamics of amoxicillin-sulbactam, a novel aminopenicillin-beta-lactamase inhibitor combination,against Escherichia coli 显示文摘 | Nicola F Arenoso HJ | 1999 | Antimicrob Agents Chemother1999，43，6： | 1 |
| 4 | Replacement of broadspectrum cephalosporins by piperacillin-tazobactam:impact on sustained high rates of bacterial resistance显示文摘 | Bantar C Vesco E Heft C | 2004 | Antimicrob Agents Chemother2004，48，2： | 1 |
| 5 | Pharmacokinetics and pharmacodynamics of amoxicillin-sulbactam, a novel aminopenicillin-beta-lactamase inhibitor combination,against Escherichia coli显示文摘 | Bantar C Nicola F Arenoso HJ etc | 1999 | Antimicrob Agents Chemother1999，43，6： | 1 |
| 6 | A pharmacodynamic model to support a 显示文摘 | Bantar C Nicola F Fernandez Canigia L etc | 2000 | J Chemother2000，12，3： | 1 |
| 7 | Pharmacokinetics and pharmacodynamics of amoxicillin-sulbactam, a novel aminopenicillin-beta-lactamase inhibitor combination against Escherichia coli 显示文摘 | Nicola F Arenoso H J | 1999 | Antirnicrob Agents Chernother1999，43，6： | 1 |
| 8 | Pharmacodynamic assessment of amoxicillin-sulbactam against Acinetobacter baumannii:searching the optimal dose and infusion time through a human ex-vivo model显示文摘 | Bantar C Canigia LF Berger MA | | 0，，5： | 1 |
| 9 | A pharamacodynamic model to support a 12 -hour dosing interval for amoxicillin/sulbactam , a novel oral combination , in the reatent of comunity - acquird lower respiratory tract infections 显示文摘 | Bantar C Nicola F Femandenz Canigial | 2000 | J Chemother2000，12，3： | 1 |
| 10 | A hospitalwide intervention program to optimize the quality of antibiotic use: impact on pre- scribing practice, antibiotic consumption, cost savings, and bacterial resistance显示文摘 | Bantar C Sartori B Vesco E et aI | 2003 | Chn Infect Dis2003，37，： | 1 |
| 11 | Replacement of broad- spectrum cephalosporins by piperacillin-tazobactam: impact on sustained high rates of bacterial resistance 显示文摘 | Bantar C Vesco E Heft C | 2004 | Antimicrob Agents Chemother2004，48，2： | 1 |
| 12 | Replacement of broad-spectrum cephalosporins by piperacillin-tazobactam: impact on sustained high rates of bacterial resistance 显示文摘 | Bantar C Vesco E Heft C | 2004 | Antimicrob Agents Chemother2004，48，2： | 1 |
| 13 | Comparative time-kill study of doxycycline, tigecycline, sulbactam, and Imipenem against several clones of Acinetobacter baumannii 显示文摘 | Bantar C Schell C Posse G | 2008 | Diagnostic Microbiology and Infectous Disease2008，61，： | 1 |
| 14 | Replacement of broad spectrum cephalosporins by piperacillin - tazobactam: impact on sustained high rates of bacterial resistance 显示文摘 | Bantar C Vesco E Heft C | 2004 | Antimicrob A- gents Chemother2004，48，： | 1 |
| 15 | Pharamacodynamic assessment of amoxicillin/sulbactam against Acinetobacter baumannii:searching the optimal dose and infusion time through a human ex-vivo model显示文摘 | Bantar C Fernandez Canigia L Alejandra Berger M | 2009 | Braz J Infect Dis2009，13，5： | 1 |
| 16 | Review of Pharma-cokinetic,Pharmacodynamic and Clinical Studies with a modern combination of amoxicillin/sulbactam显示文摘 | Soutric J Bantar C Caruso N | 2006 | Chemotherapy2006，52，4： | 1 |
| 17 | A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance显示文摘 | Bantar C Sartori B Vesco E | 2003 | Clin Infect Dis2003，37，： | 1 |
| 18 | Pharmaeokinetics and pharmacodynarnics of amoxicillin-sulbactam,a novel aminopenicillin-beta-lactamase inhibitor combination,against Escherichia col显示文摘 | BANTAR C NICOLA F ARENOSO H J | 1999 | Antimicrob Agents Chemother1999，43，6： | 1 |
| 19 | Three-year surveillance study of nosocomical bacterial resistance in Argentina显示文摘 | Bantar C Famiglietti A GoldbergM | 2010 | int J Infect Dis2010，4，2： | 1 |
| 20 | Gene therapy for gastric ulcers with single local injection of naked DNA encoding VEGF and angiopoietin-1 显示文摘 | Jones Mk Kawanaka H Bantar D | 2001 | Gastroenterology2001，121，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员